Safe - SAFE

Safehold (NYSE:SAFE) 株価情報

Safehold

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

Safehold Inc

Safe - United States Dollar

SafeMoon

SAFESTORE HLDGS PLC U/ADS by Safestore Holdings PLC

Safe and Green Development Corporation - Common Stock

Safe & Green Development Corp

Safe & Green Holdings Corp. - Common Stock

Safe & Green Holdings Corp

Safe Bulkers, Inc Common Stock ($0.001 par value)

Safe Bulkers Inc

Safe Bulkers, Inc Cumulative Redeemable Perpetual Preferred Series C (Marshall Islands)

Safe Bulkers, Inc Perpetual Preferred Series D (Marshall Islands)

Safe Haven

Safe Pro Group Inc

SAFE SUPPLY STREAMING CO by Safe Supply Streaming Co Ltd

Safe Supply Streaming Co Ltd

SafeMoon Inu

SafePal

SAFESPACE GLOBAL CORP by SafeSpace Global Corporation

SafeSpace Global Corp

SAFEGUARD SCIENTIFICS INC by Safeguard Scientifics, Inc.

Safeguard Scientifics Inc

SAFEPLUS INTL HLDGS by Safeplus International Holdings Limited

Safeplus International Holdings Ltd

Safer Shot Inc

SAFESTORE HLDGS PLC ORD by Safestore Holdings PLC

Safestore Holdings PLC

SAFETEK INTL INC by Safetek International, Inc.

Safetek International Inc

Safety Insurance Group, Inc. - Common Stock

Safety Insurance Group Inc

Safety Shot Inc

Safex Cash

Safex Token

Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>), a biopharmaceutical company specializing in inflammation and immunology (I&amp;I) biological products and which provides CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a webinar on Wednesday May 7th at, at 11:30 AM EST / 18:30 Israel time. The webinar will address the unmet needs in treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and explore Pincell's PC111, a novel monoclonal antibody targeting soluble Fas ligand (sFasL) as a promising solution.

News

SCNI

Scinai to Discuss Monoclonal Antibody PC111 for Rare Skin Diseases in Upcoming Webinar

Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.12 by 16.67 percent. This is a 7.69 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $254.52 million which beat the analyst consensus estimate of $245.79 million by 3.55 percent. This is a 2.56 percent increase over sales of $248.18 million the same period last year.

Earnings

Earnings Beats

Sotera Health Q1 Adj. EPS $0.14 Beats $0.12 Estimate, Sales $254.52M Beat $245.79M Estimate

GM CEO Barra Says Co. Assumes Pricing Will Remain What It Is Today

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $176 to $115.

Price Target

Analyst Ratings

GKOS

Needham Maintains Buy on Glaukos, Lowers Price Target to $115

Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) widens FY2025 sales outlook from $1.45 billion-$1.48 billion to $1.40 billion-$1.50 billion vs $1.46 billion estimate.

Guidance

SHAK

Shake Shack Widens FY2025 Sales Guidance from $1.45B-$1.48B to $1.40B-$1.50B vs $1.46B Est

WIIM

CNH Industrials shares are trading lower after the company reported Q1 financial results and cut its FY25 adjusted EPS guidance with its midpoint below estimates.

Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) sees Q2 sales of $346.000 million-$353.000 million vs $356.38 million analyst estimate.

Shake Shack Sees Q2 Sales $346.000M-$353.000M vs $356.38M Est

Needham analyst Charles Shi reiterates KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Buy and maintains $830 price target.

Reiteration

KLAC

Needham Reiterates Buy on KLA, Maintains $830 Price Target

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) narrows FY2025 Adj EPS guidance from $26.40-$27.00 to $26.60-$26.80 vs $26.73 analyst estimate..

Parker Hannifin Narrows FY2025 Adj EPS Guidance from $26.40-$27.00 to $26.60-$26.80 vs $26.73 Est

Rosenblatt analyst Barton Crockett maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and maintains $263 price target.

AAPL

Rosenblatt Maintains Buy on Apple, Maintains $263 Price Target

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) raises FY2025 GAAP EPS guidance from $24.46-$25.06 to $25.92-$26.12 vs $24.67 analyst estimate..

Parker Hannifin Raises FY2025 GAAP EPS Guidance from $24.46-$25.06 to $25.92-$26.12 vs $24.67 Est

MSFT: 9% &#x7C; <a href="https://www.benzinga.com//node/45128548">Microsoft shares are trading higher after the company reported Q3 financial results and beat its EPS and sales estimates. The company also issued strong revenue guidance.</a>
&nbsp;
META: 7% &#x7C; <a href="https://www.benzinga.com//node/45128558">Meta Platforms shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
LLY: -6% &#x7C; <a href="https://www.benzinga.com//node/45129537">Eli Lilly shares are trading lower after the company cut its FY25 EPS guidance.</a>

Movers

Trading Ideas

MSFT

Market-Moving News for May 1st

APi Sees Q2 Revenue Of $1.875B - $1.925B Vs. $1.854B Est.

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and maintains $204 price target.

Rosenblatt Maintains Buy on PTC, Maintains $204 Price Target

Politics

General

Secretary Bessent Says 'We Expect To See Number Revised' Referring To GDP; Says Administration Is 'Privatizing The Economy'

CORRECTION: ATI Sees Q2 Adj EPS $0.67-$0.73 vs $0.68 Est; Sees Adj. EBITDA  $195M-$205M

Acadian Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.52 by 3.85 percent. This is a 22.73 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $118.20 million which beat the analyst consensus estimate of $111.30 million by 6.20 percent. This is a 12.25 percent increase over sales of $105.30 million the same period last year.

AAMI

Acadian Asset Management Q1 Adj. EPS $0.54 Beats $0.52 Estimate, Sales $118.20M Beat $111.30M Estimate

Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) lowers FY2025 GAAP EPS guidance from $16.00-$16.50 to $15.95-$16.45 vs $16.04 analyst estimate..

HUBB

Hubbell Lowers FY2025 GAAP EPS Guidance from $16.00-$16.50 to $15.95-$16.45 vs $16.04 Est

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and maintains $18 price target.

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Maintains $18 Price Target

Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) affirms FY2025 Adj EPS guidance from $17.35-$17.85 to $17.35-$17.85 vs $17.59 analyst estimate..

Comments

Safehold

ニュース

パートナーシップ

ベンジンガ・グローバル